MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
5.77
+0.32
+5.87%
After Hours: 5.65 -0.12 -2.08% 19:33 09/28 EDT
OPEN
5.47
PREV CLOSE
5.45
HIGH
5.82
LOW
5.42
VOLUME
5.15M
TURNOVER
0
52 WEEK HIGH
25.39
52 WEEK LOW
2.865
MARKET CAP
444.99M
P/E (TTM)
-0.8179
1D
5D
1M
3M
1Y
5Y
Bluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has na...
Seekingalpha · 2d ago
US Stock Futures Mixed After Recording Losses Last Week; Fed Speakers In Focus
Pre-open movers
Benzinga · 2d ago
Amazon, bluebird bio And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Benzinga · 2d ago
Bluebird Names Katherine Breedis As Interim CFO
-SEC Filing
Benzinga · 5d ago
Short Volatility Alert: bluebird bio, Inc.
On Wednesday, shares of bluebird bio, Inc. (NASDAQ: BLUE) experienced volatile short activity. After the activity, the stock price went down -10.06% to $6.17. The overall sentiment for BLUE has been Bearish.
Benzinga · 6d ago
2 Small Caps for Growth-Focused Investors
Wall Street likes these fast-growing businesses
GuruFocus.com · 09/21 17:03
Stitch Fix, Tellurian And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving lower in today’s pre-market trading session.
Benzinga · 09/21 11:27
Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket
Gainers Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday.
Benzinga · 09/21 10:16
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s gene therapy programs in genetic diseases include programs for B-thalassemia; LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It is using a lentiviral vector (LVV) platform, it custom designs each of its therapies to address the underlying cause of disease. The Company is developing lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with SCD, a genetic disease caused by a single mutation in the B-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). The BLA for betibeglogene autotemcel (beti-cel) is for B-thalassemia in patients who receive regular red blood cell (RBC) transfusions.

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.